Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Equity Income (2016 - 2025)

Historic Equity Income for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to -$19.0 million.

  • Teva Pharmaceutical Industries' Equity Income fell 85000.0% to -$19.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$16.5 million, marking a year-over-year decrease of 155000.0%. This contributed to the annual value of -$15.0 million for FY2025, which is 140000.0% down from last year.
  • Latest data reveals that Teva Pharmaceutical Industries reported Equity Income of -$19.0 million as of Q4 2025, which was down 85000.0% from $2.0 million recorded in Q3 2025.
  • Teva Pharmaceutical Industries' Equity Income's 5-year high stood at $21.0 million during Q1 2022, with a 5-year trough of -$19.0 million in Q4 2025.
  • Its 5-year average for Equity Income is $647058.8, with a median of $1.0 million in 2022.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Equity Income surged by 60000.0% in 2022 and then crashed by 90000.0% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Equity Income (Quarter) stood at -$5.0 million in 2021, then surged by 120.0% to $1.0 million in 2022, then plummeted by 400.0% to -$3.0 million in 2023, then surged by 33.33% to -$2.0 million in 2024, then tumbled by 850.0% to -$19.0 million in 2025.
  • Its Equity Income stands at -$19.0 million for Q4 2025, versus $2.0 million for Q3 2025 and $1.0 million for Q2 2025.